Sixt SE (0NW7.IL)
| Chiusura precedente | 89,43 |
| Aperto | 87,65 |
| Denaro | 82,60 x 0 |
| Lettera | 86,80 x 0 |
| Min-Max giorno | 84,50 - 87,65 |
| Intervallo di 52 settimane | 84,50 - 170,20 |
| Volume | |
| Media Volume | 8.265 |
| Capitalizzazione | 3,385B |
| Beta (5 anni mensile) | 2,20 |
| Rapporto PE (ttm) | 9,99 |
| EPS (ttm) | 8,48 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | 3,70 (4,37%) |
| Data ex dividendo | 29 giu 2022 |
| Stima target 1A | N/D |
- GlobeNewswire
Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifunctional Fusion Protein
UM cleared to proceed with clinical trial to evaluate HCW9218 in various advanced solid tumors, such as breast, ovarian, prostate, and colorectal cancersMIRAMAR, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that the Masonic Cancer Center, University of Min
- GlobeNewswire
HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens
Preclinical Data for HCW 9218 Included in Pivotal Scientific Paper Published in Molecular TherapyMIRAMAR, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced the publication of a scientific paper, authored by the Company’s scientific research t
- GlobeNewswire
HCW Biologics’ Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute’s Annual PepTalk Conference 2022
A Novel Platform to Create Multi-Functional Immunotherapeutics for Cancer Will Feature TOBI™ Discovery Platform and Lead Product Candidate, HCW9218MIRAMAR, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced that Hing C. Wong
